ICU临终决策期间给予家属的信息手册:一项评估者盲法随机对照试验
本研究为评估者盲法随机对照试验,纳入90例预计将进行临终决策的成年患者家属,随机分为两组:第1组(n=45)接受口头信息加信息手册(说明临终决策由医生做出),第2组(n=45)仅接受口头信息。患者死亡后90天,采用事件影响量表(0-75分)盲法评估PTSD相关症状,采用医院焦虑抑郁量表(0-21分)评估焦虑抑郁症状。结果显示,第1组有PTSD相关症状的家属数显著低于第2组(18/45 vs 33/45,P=.001),第2组相对于第1组发生PTSD相关症状的风险比为1.8(95%CI 1.2-2.7);第1组事件影响量表均分(28±10 vs 38±14,P<.001)和医院焦虑抑郁量表均分(13±5 vs 17±8,P=.023)均显著低于第2组。作者认为,描述家属在临终决策中角色的信息手册显著降低了家属发生PTSD相关症状的风险。
要点
- 在ICU临终决策期间,向家属提供说明临终决策由医生做出的信息手册,可使90天时PTSD相关症状发生率从33/45降至18/45(P=.001)。
- 仅接受口头信息的家属发生PTSD相关症状的风险是接受口头信息加信息手册家属的1.8倍(RR 1.8,95%CI 1.2-2.7)。
- 信息手册组的事件影响量表均分显著低于口头信息组(28±10 vs 38±14,P<.001)。
- 信息手册组的医院焦虑抑郁量表均分显著低于口头信息组(13±5 vs 17±8,P=.023)。
适用人群与场景
- 预计将进行临终决策的成年患者的家属,共90例。
诊断标准与关键阈值
- 采用事件影响量表评估PTSD相关症状,评分范围0(无症状)至75(严重症状)。
- 采用医院焦虑抑郁量表评估焦虑和抑郁症状,评分范围0-21,评分越高症状越重。
处置流程与药物剂量
- 第1组(n=45):接受口头信息以及信息手册,手册说明临终决策由医生做出。
- 第2组(n=45):仅接受口头信息。
研究设计与关键结果
- 研究设计为评估者盲法随机对照试验,纳入90例预计进行临终决策的成年患者家属,随机分为第1组(口头信息加信息手册,n=45)和第2组(仅口头信息,n=45)。
- 患者死亡后90天,第1组有PTSD相关症状的家属为18/45,第2组为33/45,差异显著(P=.001)。
- 第2组相对于第1组发生PTSD相关症状的风险比为1.8(95%CI 1.2-2.7)。
- 第1组事件影响量表均分为28±10,第2组为38±14,第1组显著降低(P<.001)。
- 第1组医院焦虑抑郁量表均分为13±5,第2组为17±8,第1组显著降低(P=.023)。
证据类型、等级与局限
- 证据类型:评估者盲法随机对照试验。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,描述家属在临终决策中角色的信息手册显著降低了家属发生PTSD相关症状的风险。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Symptoms of posttraumatic stress disorder (PTSD) are common in family members of patients who have died in the ICU.
RESEARCH QUESTION: Could a pamphlet describing the role of relatives in the end-of-life decision decrease their risk of developing PTSD-related symptoms?
STUDY DESIGN AND METHODS: In this assessor-blinded, randomized controlled trial, 90 relatives of adult patients for whom an end-of-life decision was anticipated were enrolled. Relatives were randomly assigned to receive oral information as well as an information pamphlet explaining that the end-of-life decision is made by physicians (Group 1; n = 45) or oral information alone (Group 2; n = 45). PTSD-related symptoms were blindly assessed at 90 days following the patient's death by using the Impact of Event Scale (scores range from 0 [indicating no symptoms] to 75 [indicating severe symptoms]). Anxiety and depression symptoms were assessed by using the Hospital Anxiety and Depression Scale score (range, 0-21 [higher scores indicate worse symptoms]).
RESULTS: On day 90, the number of relatives with PTSD-related symptoms was significantly lower in Group 1 than in Group 2: 18 of 45 vs 33 of 45 (P = .001). The risk ratio of having PTSD-related symptoms in Group 2 compared with Group 1 was 1.8 (95% CI, 1.2-2.7). The mean Impact of Event Scale and Hospital Anxiety and Depression Scale scores were significantly reduced in Group 1 compared with Group 2: 28 ± 10 vs 38 ± 14 (P < .001) and 13 ± 5 vs 17 ± 8 (P = .023), respectively.
INTERPRETATION: An information pamphlet describing the relatives' role during end-of-life decisions significantly reduced their risk of developing PTSD-related symptoms.
CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov; No.: NCT02329418; URL: www.clinicaltrials.gov).
参考来源
- Robin S, Labarriere C, Sechaud G, et al. Information Pamphlet Given to Relatives During the End-of-Life Decision in the ICU: An Assessor-Blinded, Randomized Controlled Trial. Chest. 2021. PMID: 33549600. doi:10.1016/j.chest.2021.01.072
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。